Singapore Institute of Advanced Medicine Holdings Ltd.

9G2.SI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 9G2.SI stands at 30.8M. In comparison, Q0F.SI has a market cap of 18.1B. Regarding current trading prices, 9G2.SI is priced at SGD 0.03, while Q0F.SI trades at SGD 2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

9G2.SI currently has a P/E ratio of -0.97, whereas Q0F.SI's P/E ratio is 25.62. In terms of profitability, 9G2.SI's ROE is -0.38%, compared to Q0F.SI's ROE of +0.09%. Regarding short-term risk, 9G2.SI and Q0F.SI have similar daily volatility (0.00).

9G2.SI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 9G2.SI stands at 30.8M. In comparison, BSL.SI has a market cap of 1.9B. Regarding current trading prices, 9G2.SI is priced at SGD 0.03, while BSL.SI trades at SGD 1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

9G2.SI currently has a P/E ratio of -0.97, whereas BSL.SI's P/E ratio is 34.00. In terms of profitability, 9G2.SI's ROE is -0.38%, compared to BSL.SI's ROE of +0.04%. Regarding short-term risk, 9G2.SI is less volatile compared to BSL.SI. This indicates potentially lower risk in terms of short-term price fluctuations for 9G2.SI.

9G2.SI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 9G2.SI stands at 30.8M. In comparison, QC7.SI has a market cap of 422.3M. Regarding current trading prices, 9G2.SI is priced at SGD 0.03, while QC7.SI trades at SGD 0.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

9G2.SI currently has a P/E ratio of -0.97, whereas QC7.SI's P/E ratio is 22.25. In terms of profitability, 9G2.SI's ROE is -0.38%, compared to QC7.SI's ROE of +0.14%. Regarding short-term risk, 9G2.SI is less volatile compared to QC7.SI. This indicates potentially lower risk in terms of short-term price fluctuations for 9G2.SI.